Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study

Abstract

AbstractAimsTo compare the effects of baseline background characteristics in patients treated with dapagliflozin and sitagliptin in the DIVERSITY‐CVR study and to analyse the time in range (TIR), a metric for glycaemic control.Materials and methodsThis prospective, randomized, multicentre study included 340 Japanese patients with early‐stage type 2 diabetes. To examine the effects of dapagliflozin and sitagliptin on glycaemic variability, we re‐examined the primary endpoint (glycated haemoglobin [HbA1c] < 7.0%, body weight loss ≥ 3.0%, and avoidance of hypoglycaemia) achievement rate in participants stratified by baseline background characteristics.ResultsSitagliptin was significantly superior in achieving HbA1c level <7.0% in the lower body mass index (BMI) group (71.1% vs. 43.6%; P < 0.05), with no significant differences in other subgroups. In the lower BMI group, the rate of achievement of TIR > 70% after 24‐week treatment was significantly higher with sitagliptin than with dapagliflozin (91.9% vs. 69.4%; P < 0.05). In contrast, dapagliflozin was superior to sitagliptin in achieving TIR > 70% in the higher BMI group (85.7% vs. 52.9%; P < 0.01).ConclusionIn Japanese patients with early‐stage type 2 diabetes, sitagliptin was associated with improved TIR in patients with a lower BMI. Dapagliflozin was effective in patients with a higher BMI.